查找地点
有关时间、上门服务和预约查找地点
有关时间、上门服务和预约Specimen processing (i.e., N-acetyl-L-cystine-sodium hydroxide treatment or equivalent, concentration, grinding, both or neither), mycobacterial culture and smear when appropriate (smears are not performed on blood or when there is less than 2 mL of fluid). Identification by real-time polymerase chain reaction (PCR), and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, and/or nucleic acid sequencing, will be performed at an additional charge. This culture will often detect Nocardia species and other aerobic actinomyces, and identification appropriate for these organisms will be included.
48 - 56 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Bronchial washings or bronchoalveolar lavage (BAL) specimens, pleural fluid or cerebrospinal fluid (CSF)
5 mL
5 mL (Note: This volume does not allow for repeat testing.)
Sterile container with screw-cap seal
Refrigerate. If sample is to be split for other tests, specimen should be divided at the time of collection so that each portion is transported at the appropriate temperature.
Temperature | Period |
---|---|
Refrigerated | Culture: 3 days NAA: 7 days |
|
||||||
|
This test is used to detect and identify Mycobacterium tuberculosis complex and an rpoB mutation that is associated with rifampin resistance.
The assay should not be used to test specimens from patients that have been treated with antituberculous drugs for more than three days. This assay should not be used to monitor therapy or as a test of cure. A negative test does not exclude the possibility of isolating M. tuberculosis complex isolates from culture. Assay interference may occur in the presence of lidocaine, mucin, ethambutol, guaifenesin, phenylephrine, and tea tree oil. Lower sensitivity may be observed in pediatric patients due to the diffuse nature of M. tuberculosis infection in the lungs of this patient group and difficulties encountered in obtaining adequate specimens.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Microscopy, Culture, Nucleic Acid Amplification (NAA)
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf